Advanced search

Mikael Dolsten holds the position of Chief Scientific Officer & Research President at Pfizer Inc. Dr. Dolsten is also on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. In the past he occupied the position of Principal at OrbiMed Advisors LLC and Partner at OrbiMed Advisors Private Equity (a subsidiary of OrbiMed Advisors LLC), President for Wyeth Research, EVP, Global Head-Pharma Research & Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Senior Vice President for Wyeth Corp. and Member-Benefits, Law & Regulatory Committee at Wyeth Pharmaceuticals LLC. Dr. Dolsten received a doctorate from the University of Lund.

Mikael Bodin currently works as a Sales Director at ARRIS Sweden AB.

Mr. Mikael H.
Lorsell is a Portfolio Manager at Alcur Fonder AB.
Mr. Lorsell was previously employed as an Analyst by Danske Bank A/S (Sweden), a Research Analyst by Erik Penser Bank AB, and a Research Analyst by Swedbank AB (Broker).
He has a bachelor's degree in economics from Stockholm University.

Mikael Sandström worked as the Head of Products & Administrator at Cicero Fonder AB from 2015 to 2016.

Mikael Kadri is currently a Director at Grangex AB and a Partner at Trill Invest AB.
Previously, he worked as an Interim Chief Executive Officer at Monyx Asset Management AB in 2013-2014, and as a Portfolio Manager at Carnegie Fond AB in 2005-2006 and at Manticore Capital AB in 2006-2007.
Kadri is a graduate of Stockholm School of Economics.

Mikael Lyngsø is currently the Chief Executive Officer at Stibo Catalog A since 1995 and the Director at Hesehus A since 2019.
He previously worked as the Chief Executive Officer at Stibo Systems A, Director at Stibo Systems Ltd., and Software Developer at CCI Europe A.
Mr. Lyngsø completed his undergraduate degree from the University of Aarhus in 1989.